Business
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohorts\nCAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring new interim clinical data from the Phase 1/2 study of NTLA-2002 has been selected for a Distinguished Industry Abstract oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting, taking place November 10 – 14 in Louisville, Kentucky. NTLA-2002 is an investigational in vivo CRISPR/Cas9 therapy in development as a single-dose treatment to prevent angioedema attacks in people living with hereditary angioedema (HAE). Building on data released at the 2022 Bradykinin Symposium, the presentation will include additional interim safety, kallikrein reduction and attack rate data from the ongoing dose-escalation portion of Intellia’s first-in-human study of NTLA-2002. Presentation DetailsTitle: \"In vivo CRISPR/Cas9 editing of KLKB1 in Patients with Hereditary Angioedema: A First-in-Human Study” Date and Time: Saturday, November 12, 2022, from 4:30 – 5:30 p.m. ETSession: Distinguished Industry Oral Abstracts - Session APresenter: Dr. Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand Intellia Therapeutics Investor EventIntellia will host a live webcast on Monday, November 14, 2022, at 8:00 a.m. ET to review the presented data. To join the webcast, please visit this link, or the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for at least 30 days following the call. About the NTLA-2002 Clinical ProgramIntellia’s multi-national Phase 1/2 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with Type I or Type II hereditary angioedema (HAE). This includes the measurement of pla...